Sinopharm Capital
VC Fund
Shanghai, China
Sinopharm Capital is a private equity arm of China National Pharmaceutical Group Corporation that specializes in medical and healthcare, pharmaceuticals, biotechnology, medical devices, healthcare and medical supply, and services for elderly and persons with disability. It seeks to invest in China. Sinopharm Capital was founded in June 2012 and isbased in Shanghai, China.
- Total investments:
- 50
- Last investment:
- Lead investor:
- 38%
- Fund size:
- $150M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Sinopharm Capital invests in
Stages Sinopharm Capital invests in
Countries Sinopharm Capital invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Seed
- $2.9M–$16M
- Series A
- $1.4M–$28M
- Series B
- $9.2M–$114M
Investment Focus
Industry
- Health Care 30 (60%)
- Biotechnology 20 (40%)
- Medical 13 (26%)
- Pharmaceutical 11 (22%)
- Biopharma 5 (10%)
Stage
- Series A 14 (28%)
- Series B 13 (26%)
- Seed 5 (10%)
- Series C 5 (10%)
- Angel 4 (8%)
Country
- China 38 (76%)
- United States 5 (10%)
- Canada 1 (2%)
- Hong Kong 1 (2%)
- Singapore 1 (2%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Aimin Wu
President
|
President | Total investments: 1 | Find email | |
Fei Jiang
Executive Vice-President
|
Executive Vice-President | Total investments: 0 | Find email | |
|
Shengtao Zhu
Managing Director
|
Managing Director | Total investments: 0 | Find email | |
|
Xiaoming Yang
Managing Director
|
Managing Director | Total investments: 1 | Find email | |
Yong Kuang
Managing Director
|
Managing Director | Total investments: 0 | Find email | |
| See all 6 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
|
Jinju Biopharmaceuticals
|
Jinju Biotechnology is a high-tech enterprise specializing in the research and development of stem cell therapies. | Series A / Nov 19, 2025 | |
Artivila Therapeutics
|
Artivila Therapeutics is a pharmaceutical company focused on improving patient's lives through an AI-powered drug discovery engine. The company is committed to discover the best therapeutical solutions to neuro-degenerative diseases, cancers, and autoimmune diseases empowered with an integrated AI-driven innovative drug discovery platform,providing first-in-class new molecules consistently and efficiently.Artivila Therapeutics was founded in 2018 and is based in ShenZhen, China. | $15.8M / Seed / Mar 31, 2022 | |
Metanovas Biotech
|
Metanovas is a metabolic drug developer focused on combining artificial intelligence with life sciences, using deep learning. | $10M / Seed / Mar 30, 2022 | |
|
Metanovas Biotech
|
Metanovas is a metabolic drug developer focused on combining artificial intelligence with life sciences, using deep learning. | $10M / Seed / Mar 30, 2022 | |
CytoNiche
|
CytoNiche focuses on the development of 3D micro-organization engineering technology. The core technology is derived from the transformation of Tsinghua University's achievements. Based on its original research technology, Huasheng Bio has launched a series of related products and services, including customized, large-scale, automated andintelligent stem cell culture. Amplification process; 3D stem cell micro-tissue regeneration treatment of new drugs and 3D cell high-throughput drug screening products. | $47.5M / Series B / Mar 03, 2022 | |
Xishan
|
Xishan is a surgical equipment and consumables manufacturing company. | $15.7M / Series D / Dec 13, 2021 | |
Sumgen Biotech
|
Jianjian Biotechnology is an antibody drug developer, specializing in the development of therapeutic antibody drugs and the application of antibodies in immunotherapy and immunodiagnosis. Based on CD&MD innovative antibody research and development technology, it has developed products such as tumor immunotherapy antibody drugs and CARTantibodies. . | Dec 07, 2021 | |
|
Sumgen Biotech
|
Jianjian Biotechnology is an antibody drug developer, specializing in the development of therapeutic antibody drugs and the application of antibodies in immunotherapy and immunodiagnosis. Based on CD&MD innovative antibody research and development technology, it has developed products such as tumor immunotherapy antibody drugs and CARTantibodies. . | Series B / Dec 07, 2021 | |
Longhui Medical
|
Longhui Medical is a medical robotics R&D company focused on joint replacement surgery robots, product development, sales, and service. | $15.6M / Series B / Nov 26, 2021 | |
Sepax Technologies
|
Sepax Technologie is a biotechnology firm that offers ion exchange, hydrophobic interaction, and method development services. | $78.3M / Series D / Nov 15, 2021 | |
| See all 50 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Sinopharm Capital invest in?
Sinopharm Capital invests primarily in Health Care, Biotechnology and Medical startups, most often at Series A and Series B stage. Most of the 50 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Sinopharm Capital's check size?
Sinopharm Capital typically joins rounds of $2.9M–$16M at Seed, $1.4M–$28M at Series A and $9.2M–$114M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Sinopharm Capital participates in.
How do I contact Sinopharm Capital?
Public channels for Sinopharm Capital include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Sinopharm Capital?
The team at Sinopharm Capital includes Aimin Wu (President), Fei Jiang (Executive Vice-President) and Shengtao Zhu (Managing Director), among 6 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
